Division of General Internal Medicine
Published on Division of General Internal Medicine (https://gim.uw.edu)

Home > Bruce M. Psaty, MD, PhD, MPH

Bruce M. Psaty, MD, PhD, MPH

Bruce Psaty, headshot
Professor
Medicine
Professor
Epidemiology
Adjunct Professor
Health Services
Co-director, Cardiovascular Health Research Unit

Faculty Information

Biography
Education & Training: 
PhD, English language and literature
Indiana University
Bloomington, IN
1979
MD
Indiana University, School of Medicine
Indianapolis, IN
1981
Residency in Internal Medicine
Indiana University Medical Center
Indianapolis, IN
1984
MPH
University of Washington
Seattle, WA
1986
Honors: 
Remington Methodology Lecturer, AHA Epidemiology and Prevention Council
2004
School of Public Health and Community Medicine Outstanding Faculty Community Service Award
2005
University of Washington Outstanding Public Service Award for Work in Drug Safety
2005
Ancel Keys Memorial Lectureship, American Heart Association National Meeting
2009
Member, US Food and Drug Administration Science Board
2011–2018
Member, National Heart, Lung, Blood Institute Advisory Council
2012–2017
Designated Distinguished Scientist by the American Heart Association
2013
Elected to the Institute of Medicine of the National Academies of Science
2013
University of Washington, School of Public Health Distinguished Alumni Award
2018
Member, National Heart, Lung, and Blood Institute Board of External Experts
2018–
Contact
Email: 
psaty@uw.edu [1]
Research & Clinical Interests
Research Interests: 

Myocardial infarction, venous thrombosis, and stroke
Hypertension, hyperlipidemia, diabetes, and atrial fibrillation
Pharmacoepidemiology
Genetics, genomics, and pharmacogenetics
Epidemiologic methods

Publications
Publications: 
  • Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD. The risk of myocardial infarction associated with anti-hypertensive drug therapies [2]. JAMA 1995; 274: 620–625.
  • Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: A network meta-analysis [3]. JAMA 2003; 289: 2534–2544.
  • Psaty BM, Kronmal RA. Reporting mortality findings in trials of rofecoxib for Alzheimer disease or cognitive impairment: A case study based on documents from rofecoxib litigation [4]. JAMA. 2008 Apr 16;299(15):1813–7.
  • Psaty BM, O’Donnell CJ, Gudnason V, Kunetta KL, Folsom AR, Rotter JI, Uitterlinden AG, Harris TB, Witteman JCM, Boerwinkle E on behalf of the CHARGE Consortiu. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from 5 cohorts [5]. Circ Cardiovasc Genet 2009; 2: 73–80.
  • Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, … Psaty BM#, Abecasis GR#, Chakravarti A#, Elliott P#, van Duijn CM#, Newton-Cheh C#, Levy D#, Caulfield MJ#, Johnson T#. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk [6]. Nature. 2011 Sep 11;478(7367):103–9. #These authors contributed equally.

Source URL: https://gim.uw.edu/faculty/bruce-m-psaty-md-phd-mph

Links
[1] mailto:psaty@uw.edu
[2] https://www.ncbi.nlm.nih.gov/pubmed/?term=7637142
[3] https://www.ncbi.nlm.nih.gov/pubmed/?term=12759325
[4] https://www.ncbi.nlm.nih.gov/pubmed/?term=18413875
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2875693/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3340926/